Envestnet Asset Management Inc Bridge Bio Pharma, Inc. Transaction History

Envestnet Asset Management Inc

$299 Billion
Q1 2025

A detailed history of Envestnet Asset Management Inc transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 12,987 shares of BBIO stock, worth $560,778. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,987

Previous 12,926 0.47%

Holding current value

$560,778

Previous $354,000 26.55%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 29, 2025	BUY	$28.12 - $37.59 $1,715 - $2,292	61 Added 0.47%	12,987 $448,000
Q4 2024 Feb 12, 2025	SELL	$22.35 - $29.5 $65,910 - $86,995	-2,949 Reduced 18.58%	12,926 $354,000
Q3 2024 Nov 06, 2024	SELL	$23.91 - $31.3 $258,562 - $338,478	-10,814 Reduced 40.52%	15,875 $404,000
Q2 2024 Aug 08, 2024	SELL	$23.0 - $31.04 $140,576 - $189,716	-6,112 Reduced 18.63%	26,689 $676,000
Q1 2024 May 13, 2024	SELL	$27.35 - $40.45 $97,311 - $143,921	-3,558 Reduced 9.79%	32,801 $1.01 Million
Q4 2023 Feb 13, 2024	BUY	$24.02 - $43.89 $170,662 - $311,838	7,105 Added 24.29%	36,359 $1.47 Million
Q3 2023 Nov 13, 2023	BUY	$16.89 - $35.01 $136,640 - $283,230	8,090 Added 38.23%	29,254 $771,000
Q2 2023 Aug 04, 2023	BUY	$13.29 - $18.01 $5,807 - $7,870	437 Added 2.11%	21,164 $364,000
Q1 2023 May 11, 2023	BUY	$7.17 - $18.55 $61,626 - $159,437	8,595 Added 70.85%	20,727 $343,000
Q4 2022 Feb 07, 2023	SELL	$6.74 - $11.52 $1,678 - $2,868	-249 Reduced 2.01%	12,132 $92,000
Q3 2022 Nov 10, 2022	BUY	$7.94 - $12.36 $98,305 - $153,029	12,381 New	12,381 $123,000

Others Institutions Holding BBIO

# of Institutions

362

Shares Held

185M

Call Options Held

12.8M

Put Options Held

2.09M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $6.4B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.

Account

Envestnet Asset Management Inc Bridge Bio Pharma, Inc. Transaction History